And Eli Lilly researchers are conducting clinical trials for the newest GLP-1 drug, called retatrutide, which could help patients lose as much as 30% of their body weight
Maximizing Your 2025 Health and Wellness Transformation As we navigate 2025, the integration of gut health and metabolic support represents the cutting edge of wellness innovation
Additional sources were identified through manual screening of the references of key articles to ensure comprehensive coverage of the topic
Like other classes of GLP-1 analogs, the most commonly reported adverse effects of exenatide LAR treatment include nausea, vomiting, diarrhea, and mild hypoglycemia [68,69]
How susceptible are consumers to deceptive advertising claims
Glycoconj J 1995;12(3):258267